Vectus Biosystems

Vectus Biosystems Accounts Payable

The Accounts Payable of Vectus Biosystems (VBS.AX) as of Nov 5, 2026 is 600,657.00 AUD. In the previous year, Accounts Payable was 533,995.00 AUD — a change of 12.48% (higher).

Accounts Payable

600,657.00AUD

YoY

12.48%

Last updated:

Accounts Payable of Vectus Biosystems is 2026 600,657.00 AUD. Accounts Payable of Vectus Biosystems was 2025 533,995.00 AUD. It decreases by 12.48% higher compared to the previous year.

The Vectus Biosystems Accounts Payable history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Accounts Payable
Date
Accounts Payable
Jan 1, 2019
1.12 M AUD
Jan 1, 2020
606,201.00 AUD
Jan 1, 2021
120,350.00 AUD
Jan 1, 2022
219,570.00 AUD
Jan 1, 2023
219,570.00 AUD
Jan 1, 2024
187,062.00 AUD
Jan 1, 2025
533,995.00 AUD
Jan 1, 2026
600,657.00 AUD
The Vectus Biosystems Accounts Payable history
YEARAccounts PayableYoY
600,657.00AUD+12.48%
533,995.00AUD+185.46%
187,062.00AUD-14.81%
219,570.00AUD0.00%
219,570.00AUD+82.44%
120,350.00AUD-80.15%
606,201.00AUD-45.87%
1.12 MAUD+14.16%
980,986.00AUD+1,231.11%
73,697.00AUD-77.63%
329,511.00AUD+91.18%
172,353.00AUD-37.70%
276,643.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vectus Biosystems Stock analysis

What does Vectus Biosystems do? Vectus Biosystems Ltd. generates revenue through the development and commercialization of pharmaceutical products targeting fibrotic diseases and hypertension. The company focuses on VB0004, a compound designed to treat tissue hardening and high blood pressure, alongside candidates for fibrotic liver conditions like NASH and pulmonary fibrosis. Its subsidiary Accugen Pty Limited offers the Accugen platform, which provides qPCR reagents and software for accurate DNA and RNA quantification in laboratory testing. The primary buyers of these products are pharmaceutical companies and research institutions seeking advanced drug development tools and therapies for fibrotic disorders. Vectus Biosystems targets the medical research and development sector, specifically addressing unmet needs in fibrotic disease treatment. The Accugen platform serves laboratories requiring efficient molecular analysis tools, with its technology enhancing the speed and precision of qPCR testing. The company’s revenue streams are derived from both therapeutic product development and the sale of diagnostic solutions to biotech firms and academic research entities. The firm’s focus on fibrosis-related treatments, including heart, kidney, and liver diseases, positions it within niche therapeutic segments. Accugen’s reagents and software are sold to laboratories as part of the qPCR workflow, supporting drug discovery processes. Pharmaceutical companies and research organizations are the key segments purchasing Vectus Biosystems’ products for their R&D pipelines and clinical applications. Vectus Biosystems is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vectus Biosystems stock

Accounts Payable of Vectus Biosystems is 600,657.00 AUD in 2026.

Accounts Payable of Vectus Biosystems changed from 533,995.00 AUD to 600,657.00 AUD, representing a 12.48% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Payable Vectus Biosystems since 2006 – with annual values, charts, and detailed analysis.

Accounts payable represents money owed to suppliers for goods and services received. It is a key component of working capital management.

Accounts Payable's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Payable's Vectus Biosystems historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Vectus Biosystems

All Key Metrics — Vectus Biosystems